Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164746 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| SCHEMBL20589790 | 0.85 | CRHBP (0.49) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| SCHEMBL9300807 | 0.84 | EIF4E (0.47) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| SCHEMBL147187 | 0.84 | AKR1C3 (0.63) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| Methyl Alcohol SCHEMBL28009562 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| Hydrochloric Acid SCHEMBL11773334 | 0.83 | AKR1C3 (0.61) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| SCHEMBL15440376 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| SCHEMBL1791669 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT | |
| SCHEMBL9940716 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPTPDK1MEN1 | |
| SCHEMBL2617463 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KMT2AAKR1C3AKR1C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-10-20 | — | — | US | disclosed |
| EP-3638229-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018232094-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| EP-2646417-A1 | KAT II INHIBITORS | Pfizer Inc (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8487104-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487104-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487104-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2012073146-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012073146-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142729-A1 | KAT ll INHIBITORS | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142729-A1 | KAT ll INHIBITORS | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142729-A1 | KAT ll INHIBITORS | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885KMT2A 906/4885AKR1C3 1484/4885 |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885KMT2A 906/4885AKR1C3 1484/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885KMT2A 906/4885AKR1C3 1484/4885 |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885KMT2A 906/4885AKR1C3 1484/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885KMT2A 906/4885AKR1C3 1484/4885 |
| US-20120142729-A1 | KAT ll INHIBITORS | KAT7, KAT2A, KATNA1 | ALDH1A1 2408/4885KMT2A 68/4885AKR1C3 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.